A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors

PURPOSE: This phase I study investigated the safety, dose limiting toxicity, and efficacy in three cohorts all treated with the mTOR inhibitor everolimus that was delivered 1) in combination with 5-fluourouracil with leucovorin (5-FU/LV), 2) with mFOLFOX6 (5-FU/LV + Oxaliplatin), and 3) with mFOLFOX...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Chemother Pharmacol
Egile Nagusiak: McRee, Autumn J., Davies, Janine M., Sanoff, Hanna G., Goldberg, Richard M., Bernard, Stephen, Dees, E. Claire, Keller, Kimberly, Ivanova, Anastasia, O'Neil, Bert H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4517671/
https://ncbi.nlm.nih.gov/pubmed/24819684
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2474-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak